EverImmune secures €3.5M from Bpifrance to fund drug trial in cancer patients

French biotech company EverImmune, has secured €3.46 million in funding from a Bpifrance, under the ‘Innovation in biotherapeutics’ scheme. The funding is a mix of subsidies and repayable loans.

EverImmune specialises in the development of live biotherapeutic products in the field of microbiota oncology, the funding will allow the biotech firm to conduct clinical trials on a cancer drug candidate. It will fund phase I/II of the clinical trial for Oncobax® AK. The trial will have recruit 71 trial patients, in fifteen hospitals in France and Belgium with Non-Small Cell Lung Cancer (NSCLC) or Renal Cell Cancer (RCC). The trail will determine if the drug improves the effectiveness of the patients’ immunotherapy treatment. 

EverImmune also develops other bacteria in its pipeline for use in the treatment of different types of cancer, such as breast and colon cancers.

Lead image: via Upsplash. Photo: Louis Reed.